将曲妥珠单抗（无论是否联合帕妥珠单抗）纳入HER2阳性胃癌围手术期化疗：INNOVATION试验（欧洲癌症研究与治疗组织-1203-胃肠道肿瘤协作组） - Suppr | 超能文献

Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2- Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG).

出版信息

Oncol Res Treat. 2016;39(3):153-4; discussion 155. doi: 10.1159/000444702.

DOI:10.1159/000444702

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Integration of Trastuzumab, with or without Pertuzumab, into Perioperative Chemotherapy of HER2- Positive Stomach Cancer: The INNOVATION Trial (EORTC-1203-GITCG).将曲妥珠单抗（无论是否联合帕妥珠单抗）纳入HER2阳性胃癌围手术期化疗：INNOVATION试验（欧洲癌症研究与治疗组织-1203-胃肠道肿瘤协作组）

Oncol Res Treat. 2016;39(3):153-4; discussion 155. doi: 10.1159/000444702.

2

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。

BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.

3

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?曲妥珠单抗联合化疗在 2 neu 阳性局部胃腺癌围手术期治疗中有优势吗？

World J Surg Oncol. 2011 Sep 28;9:112. doi: 10.1186/1477-7819-9-112.

4

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.局部晚期、炎症性或早期 HER2 阳性乳腺癌患者新辅助帕妥珠单抗和曲妥珠单抗的 5 年分析（NeoSphere）：一项多中心、开放性标签、2 期随机试验。

Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11.

5

[A case of curative surgery for HER2-positive gastric cancer after chemotherapy using paclitaxel combined with trastuzumab].[1例经紫杉醇联合曲妥珠单抗化疗后行HER2阳性胃癌根治性手术的病例]

Gan To Kagaku Ryoho. 2014 Nov;41(12):2302-4.

6

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。

Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.

7

Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.分析HER家族（HER1-4）表达作为帕妥珠单抗、曲妥珠单抗和多西他赛联合治疗晚期HER2阳性乳腺癌的生物标志物

Anticancer Res. 2018 Apr;38(4):2285-2294. doi: 10.21873/anticanres.12473.

8

First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer.厄瑞布林联合曲妥珠单抗和帕妥珠单抗治疗晚期 HER2 阳性乳腺癌的首次报告。

Breast. 2017 Oct;35:78-84. doi: 10.1016/j.breast.2017.06.015. Epub 2017 Jun 27.

9

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.曲妥珠单抗为基础的治疗后帕妥珠单抗单药治疗及后续曲妥珠单抗再引入：晚期人表皮生长因子受体 2 阳性乳腺癌患者的疗效和耐受性。

J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5.

10

HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.接受曲妥珠单抗治疗的 HER2 阳性患者与 HER2 阴性晚期胃癌患者具有可比的预后：一项前瞻性队列观察。

Int J Cancer. 2014 May 15;134(10):2468-77. doi: 10.1002/ijc.28559. Epub 2013 Nov 8.

引用本文的文献

1

Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population.HER2状态对西方人群中切除的胃或胃食管交界腺癌的影响。

Ecancermedicalscience. 2020 Mar 24;14:1020. doi: 10.3332/ecancer.2020.1020. eCollection 2020.

2

Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective.食管胃交界部癌的多模式治疗策略：西方视角

J Gastric Cancer. 2019 Jun;19(2):148-156. doi: 10.5230/jgc.2019.19.e19. Epub 2019 May 24.

3

The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience.不可切除食管癌和胃癌的降期治疗方法：单中心经验

J Gastrointest Oncol. 2019 Jun;10(3):499-505. doi: 10.21037/jgo.2019.01.32.